Elicio Therapeutics (ELTX) – Analysts’ Weekly Ratings Changes

Elicio Therapeutics (NASDAQ: ELTX) recently received a number of ratings updates from brokerages and research firms:

• 6/18/2026 – Elicio Therapeutics is now covered by LADENBURG THALM/SH SH. They set a “buy” rating and a $12.00 price target on the stock.
• 6/16/2026 – Elicio Therapeutics was downgraded by JonesTrading from “buy” to “hold”.
• 6/15/2026 – Elicio Therapeutics had its “buy” rating reaffirmed by Rodman & Renshaw.
• 6/15/2026 – Elicio Therapeutics had its price target raised by HC Wainwright from $17.00 to $23.00. They now have a “buy” rating on the stock.
• 6/10/2026 – Elicio Therapeutics is now covered by B. Riley Financial, Inc.. They set a “buy” rating and a $27.00 price target on the stock.
• 5/28/2026 – Elicio Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $17.00 price target on the stock.
• 5/16/2026 – Elicio Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 4/24/2026 – Elicio Therapeutics had its “sell (e+)” rating reaffirmed by Weiss Ratings.

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.